Antagonist of the BTLA/HVEM interaction for use in therapy
US10005839B2 · kind B2 · utility
0Cited by
1References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 21, 2014 |
| Grant date | Jun 26, 2018 |
| Priority date | — |
| Expiry date | Feb 21, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of Vγ9Vδ2 T cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.